In BRAF-mutant colorectal cancer, BRAF inhibitors trigger resistance through an alternative mechanism, as EGFR signaling is upregulated (Prahallad et al., 2012; Corcoran et al., 2012). This evidence concerns the gene BRAF and colorectal cancer.